Literature DB >> 15205570

Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth.

Woo Sung Moon1, Kenneth J Chang, Adhip P N Majumdar, Andrzej S Tarnawski.   

Abstract

BACKGROUND/AIMS: The mitogenic signaling pathway of epidermal growth factor receptor (EGFR) is activated in a variety of cancers, including hepatocellular carcinoma (HCC). The recently cloned EGFR-related protein (ERRP) has been proposed to be a negative regulator of EGFR. The expression of ERRP in non-malignant liver cells and in HCC, and its relation to cell proliferation, have not been examined.
METHODS: Paraffin sections of formalin-fixed HCC specimens of 51 HCCs and 10 normal liver specimens were immunostained with anti-ERRP and anti-p53 antibodies. To determine the relationship between ERRP expression and cell proliferation, we performed double staining for ERRP and proliferating cell nuclear antigen (PCNA) in the same HCC specimens.
RESULTS: In normal liver, ERRP was expressed in 100% of specimens, while in non-malignant liver tissue from HCC, ERRP expression was present in 50% of the specimens (p < 0.001). In contrast, ERRP expression was present only in 14% of the HCC specimens. The expression of ERRP in cancer cells was inversely correlated with proliferative activity and tumor size (p < 0.001, p < 0.05, respectively). No significant correlation was found between p53 expression and the expression of ERRP.
CONCLUSIONS: Human HCC, which has been shown to be associated with increased activation of EGFR, exhibits a substantial reduction in ERRP expression. The inverse relationship between ERRP expression, proliferative activity of tumor cells and tumor size suggests that in some HCC, ERRP is a negative regulator of HCC growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205570     DOI: 10.1159/000079151

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

Review 1.  EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.

Authors:  Jyoti Nautiyal; Shailender Singh Kanwar; Adhip P N Majumdar
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

Review 2.  Emerging therapies in gastrointestinal cancers.

Authors:  Jyoti Nautiyal; Arun K Rishi; Adhip P N Majumdar
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

3.  Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays.

Authors:  Evangelos Tsiambas; Loukas Manaios; Costas Papanikolopoulos; Dimitrios N Rigopoulos; Dimitrios Tsounis; Andreas Karameris; Aspasia Soultati; Antigoni Koliopoulou; Christos Kravvaritis; Theodoros Sergentanis; Efstratios Patsouris; Spyridon Dourakis
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

4.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.